BACKGROUND Growth hormone (GH) has been used to promote growth in both the short and long term in a number of dysmorphic syndromes, including Turner syndrome. As this condition shares many clinical ...

There’s also Turner syndrome and Noonan syndrome, both of which can lead to physical differences such as short stature, heart defects, and developmental or learning delays. Rare disease can affect any ...

N) today presented data from the Phase III REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was ...

Topline data were announced from a phase 3 trial evaluating somapacitan in children born small for gestational age, with Noonan syndrome, or with idiopathic short stature.

Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or ...

evaluated the efficacy and safety of somapacitin in children aged 2 to 10 years born small for gestational age (SGA), or with Turner Syndrome (TS), Noonan syndrome (NS), or idiopathic short ...

The Danish pharmaceutical giant said the drug was more effective than a daily growth hormone in children with Noonan syndrome--a genetic condition that stops typical development in some parts of ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more ...

Dion's recent Eurovision appearance has renewed focus on her diagnosis of Stiff Person Syndrome, a rare neurological ...

In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm/year with daily somatropin. Don’t miss this list of 3 high-yield stocks—including one delivering over 10%—built for ...